Novel Nicotine Products’ Potential in Harm Reduction Gets Appropriators’ Nod
This article was originally published in The Tan Sheet
Executive Summary
In its report on the fiscal 2016 spending bill it approved for FDA and USDA, the Appropriation Committee says sustaining 2007 cut-off date is unfair to electronic cigarettes and other yet-regulated tobacco and nicotine products already available.
You may also be interested in...
In Brief
FDA encourages disclosures at public hearings
California Prop 65 Complaints Against OTC Generics? Ranitidine Could Be First And Last Target
Marketers of copies of national brand OTCs are required under FDA regulations to use the same labeling as the brand, a rule that in effect has limited complaints in California state court alleging Prop 65 violations with nonprescription drug labeling to targeting branded product marketers.
Federal Preemption Strikes California Prop 65 Complaint Against Generic OTC Ranitidine Firms
Whether California court finds Zantac, when marketed containing ranitidine, should have had a Prop 65 label warning could be influenced by dismissal in federal court of class action complaints due to faulty research behind claims that ranitidine causes a carcinogenic substance to form post-production.